The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.10
Bid: 9.70
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 0.80 (8.247%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 10.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

26 Jul 2011 13:01

For filings with the FSA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are Scancell Holdings plc attached:ii 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments An event changing the breakdown of voting rights Other (please specify): 3. Full name of person(s) subject to the Calculus Capital Limitednotification obligation:iii 4. Full name of shareholder(s) HSBC Global Custody (UK) Limited (if different from 3.):iv 5. Date of the transaction and date on which the threshold is crossed or 26 July 2011reached: v 6. Date on which issuer notified: 26 July 2011 7. Threshold(s) that is/are crossed or 10,11,12,13%reached: vi, vii 8. Notified details: A: Voting rights attached to shares viii, ix Class/type Situation previous Resulting situation after the triggering of to the triggering transaction shares transaction Number Number Number Number of voting % of voting rightsif possible of of of shares rights x using Shares Voting the ISIN Rights Direct Direct xi Indirect Direct Indirect CODE xii Ordinary Shares ISIN: 15,277,780 15,277,780 25,277,780 25,277,780 13.02 % GB00B39J5N63 B: Qualifying Financial Instruments Resulting situation after the triggering transaction Type of Expiration Exercise/ Number of voting % of voting financial date xiii Conversion Period xiv rights that may be rights instrument acquired if the instrument is exercised/ converted. C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi Resulting situation after the triggering transaction Type of Exercise price Expiration Exercise/ Number of voting % of voting financial date xvii Conversion rights instrument rights xix, xx instrument period refers to xviii Nominal Delta Total (A+B+C) Number of voting rights Percentage of voting rights 25,277,780 13.02 %

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

N/A Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease N/Ato hold: 12. Date on which proxy holder will cease to hold N/Avoting rights: 13. Additional information: N/A 14. Contact name: Calculus Capital Limited 15. Contact telephone number: 0207 493 4940

Note: Annex should only be submitted to the FSA not the issuer Annex: Notification of major interests in sharesxxii A: Identity of the persons or legal entity subject to the notification obligation Full name (including legal form of legal entities) Contact address (registered office for legal entities) Phone number & email Other useful information (at least legal representative for legal persons)

B: Identity of the notifier, if applicable Full name Contact address Phone number & email Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation) C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

XLON
Date   Source Headline
20th Jul 20167:00 amRNSExtension to Ichor Commercial Option
13th Jul 20167:00 amRNSPeer-reviewed publication on Moditope® platform
6th Jul 20167:00 amRNSSCIB1 compelling survival data in melanoma
29th Jun 20164:40 pmRNSSecond Price Monitoring Extn
29th Jun 20164:35 pmRNSPrice Monitoring Extension
17th Jun 20167:00 amRNSSCIB1 Drug Product Supply
2nd Jun 20167:00 amRNSDevelopment of ImmunoBody® Vaccine
18th May 20167:00 amRNSOpens US Headquarters in San Diego
19th Apr 20167:00 amRNSDirector/PDMR Shareholding
11th Apr 20164:11 pmRNSHolding(s) in Company
6th Apr 20167:00 amRNSHolding(s) in Company
4th Apr 201610:17 amRNSResult of the open offer
1st Apr 20167:00 amRNSResult of open offer
23rd Mar 20167:00 amRNSWorld Cancer Vaccine Congress
11th Mar 20167:00 amRNSStrategic collaboration with Karolinska Institutet
11th Mar 20167:00 amRNSPosting of Circular
9th Mar 20162:07 pmRNSPlacing and Open Offer Close
9th Mar 20167:00 amRNSProposed Placing and Open Offer
23rd Feb 20167:00 amRNSPresenting at the Biotech Capital Conference
27th Jan 20169:00 amRNSAmendment to Options
27th Jan 20167:00 amRNSHalf Yearly Report
11th Jan 20167:00 amRNSSCIB1 Early Immune Effect Observed by ImmunTraCkeR
7th Jan 20167:00 amRNSDirectorate Change
5th Jan 20167:00 amRNSKey Moditope paper published in Cancer Research
18th Dec 20157:00 amRNSUS Phase II combination study with SCIB1
20th Oct 20151:05 pmRNSResults of AGM
20th Oct 20157:00 amRNSAGM Business Update
14th Oct 20157:00 amRNSDirectorate Change
6th Oct 20157:00 amRNSSix scientific presentations at PIVAC Conference
18th Sep 20157:00 amRNSFinal Results for the year ended 30 April 2015
16th Sep 20157:00 amRNSImmunoBody presented at Cancer Vaccines Conference
27th Aug 20154:42 pmRNSNotice of AGM
30th Jul 20157:00 amRNSCollaboration with ImmunID
9th Jul 20157:00 amRNSPatient recruitment completed for SCIB1 trial
2nd Jun 20157:00 amRNSSCIB1 data update in resected melanoma patients
17th Apr 20159:00 amRNSPoster on Moditope to be presented at AACR
24th Mar 20154:40 pmRNSSecond Price Monitoring Extn
24th Mar 20154:35 pmRNSPrice Monitoring Extension
24th Mar 20157:00 amRNSSCIB2 synergy with checkpoint inhibitor blockade
12th Jan 20157:00 amRNSPositive SCIB1 Phase 1/2 clinical trial update
15th Dec 20145:22 pmRNSHolding(s) in Company
10th Dec 20147:00 amRNSHalf Yearly Report
22nd Oct 20143:07 pmRNSChange of Registered Office
14th Oct 20146:19 pmRNSResult of AGM
14th Oct 20147:00 amRNSAppointment of Nominated Adviser and Broker
14th Oct 20147:00 amRNSAGM research and development update
30th Sep 20147:00 amRNSPresent at the 14th Annual Biotech in Europe Forum
19th Sep 20149:57 amRNSNotice of AGM
12th Sep 20147:00 amRNSPresenting at Upcoming Scientific Conferences
4th Sep 20147:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.